REIMAGINE
Summary
This study is being done to better understand how well the medication mepolizumab (NUCALA) is working in routine medical practice to treat a sub-population of adult patients with severe asthma who have what is termed an eosinophilic phenotype (SA-EP). Mepolizumab is approved (marketed drug) in Canada.
Study participants will be asked to complete questionnaires and lung function testing in addition to their standard of care visit.
Participation in the study will last 2 years.
Eligibility
Eligible gender: Male, Female, Transgender, Other
Eligible ages: 18 to 80
Inclusion criteria:
You might be eligible if:
1) 18 years or over
2) You have severe asthma with an eosinophilic phenotype
3) You have been prescribed NUCALA
Exclusion criteria:
You may not be eligible if:
1) Under the age of 18
2) You do not have severe asthma with an eosinophilic phenotype
3) You are pregnant
4) You are a current smoker
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
If you are interested in learning more about this study, please contact the study coordinator, Madison, at 403-210-7827.
Principal investigator:
Richard Leigh
Clinical trial:
Yes
REB-ID:
REB24-0130